Maze (MAZE) CMO Harold Bernstein Exercises Options, Sells Shares

What Happened Harold Bernstein, President, R&D & Chief Medical Officer of Maze Therapeutics, exercised stock options for 16,142 shares on August 13, 2026 at an exercise price of $10.42 (cost $168,200). He then sold those 16,142 shares in an open-market transaction at a weighted average price of $27.61 for total proceeds of $445,621. The exercise/conversion of the option is also reported as a derivative disposition at $0. Net proceeds before fees and taxes were approximately $277,421.

Key Details

• Transaction date: August 13, 2026 (Form 4 filed Aug 14, 2026; timely).
• Exercise (code M): 16,142 shares acquired at $10.42 each (total $168,200).
• Sale (code S): 16,142 shares sold at weighted avg $27.61 (total $445,621); sale prices ranged $27.17–$28.00 per share (footnote F2).
• Derivative line (code M): same options shown as disposed at $0 upon conversion.
• Plan note: Sale was effected under a Rule 10b5-1 trading plan adopted Sept 29, 2025 (footnote F1).
• Vesting: Option vested initially 1/4 on Oct 3, 2023 and 1/48 monthly thereafter (footnote F3).
• Shares owned after transaction: not specified in the provided data.

Context Because the exercised shares were sold the same day, this is effectively a cashless exercise (exercise followed by immediate sale). The sale was prearranged under a 10b5-1 plan, meaning the transactions were executed according to a previously adopted trading plan rather than an ad hoc decision on the sale date. This filing is factual disclosure of the exercise and sale; it does not by itself indicate the insider’s broader view of the company.